Uma Borate, Acute Leukemia Translation Lead, Assistant Professor at OHSU, shared on X:
“Out in Blood Journals Portfolio!
OPTI-AML,Ph 2 randomized study of Aza+28D (AV28) vs 14D(AV14) Ven for first 2 cycles in AML pts >=60 yrs.
This study generated a lot of discussion so here are all the relevant details about this first prospective Ven dose optimization study!”
Title: OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML
Authors: Uma M Borate, Ying Huang, Tara L. Lin, Shivani Handa, Ronan Swords, Curtis A. Lachowiez, Elie Traer, Wendy Stock, Olatoyosi Odenike, Anand A Patel, Maria R Baer, Vu H. Duong, Eytan M. Stein, William Blum, Colin Anthony Vale, Emily Curran, Yazan F. Madanat, Rebecca L. Olin, Gary J. Schiller, Angela D Nichols, Lacey Williams, Nyla A. Heerema, Mary F Johnson, Timothy L Chen, Sonja Marcus, Molly Martycz, Mona Stefanos, Leonard Rosenberg, Louis James DeGennaro, Lore Gruenbaum, Amy Burd, John C Byrd, Brian J. Druker, Ross L Levine, Ashley O Yocum, Alice S. Mims, Joshua F Zeidner
To which Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina at Chapel Hill, added:
“OPTI-AML published in Blood Journals Portfolio led by the inimitable Uma Borate.
This highly impactful study funded by Blood Cancer United Research emphasizes the importance of randomized trials in AML.
Grateful to be part of this amazing team with Beat AML.”
Other articles about AML on OncoDaily.